The therapeutic approach of immune checkpoint inhibitors has revolutionized the long-term survival of melanoma patients, but has also reached its limits. Innovative approaches such as adoptive T-cell therapy and personalized mRNA vaccines offer new hope. In addition, the neoadjuvant paradigm has shown that the right timing of therapy can be a decisive factor.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- H. pylori infection: current study data
Fewer gastric carcinomas and peptic ulcers after eradication
- From symptom to diagnosis
Pneumology – tracheal and bronchial calcifications
- Tinea capitis: Current Guidelines and Recommendations
What should be kept in mind when treating adult patients?
- Geriatric patients
Micronutrient Intake in Older Adults
- Crohn's disease: focus on long-term results
“Top-down” approach or classic step therapy?
- SwissDiab Study: New Analysis Published
How are diabetes complications associated with quality of life?
- Pre-acclimatization on Mount Everest
Exploring the physiological limits
- Viloxazine for ADHD